Company news

Lantern Pharma Inc. news in 2024

Lantern Pharma Inc.'s news releases, calls and decks from 2024, newest first.

View company

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

December 8, 2024

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

December 2, 2024

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

November 25, 2024

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

November 18, 2024

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

November 6, 2024

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

November 4, 2024

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4: 30 p.m. ET

October 30, 2024

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

October 22, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October

October 20, 2024

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

October 14, 2024

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers

September 22, 2024

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

August 7, 2024

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

August 6, 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

August 4, 2024

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4: 30 p.m. ET

July 31, 2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

July 9, 2024

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

June 11, 2024

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 8, 2024

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 5, 2024

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4: 30 p.m. ET

May 1, 2024

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

April 23, 2024

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

April 21, 2024

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

March 17, 2024

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

March 14, 2024

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4: 30 p.m. ET

March 10, 2024

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

March 4, 2024

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

March 3, 2024

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

February 14, 2024

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

January 16, 2024

Calls in 2024

Decks in 2024